Bioceres Crop Solutions (LTN) 10-K 5 Mar 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jan. 31, 2019	Mar. 04, 2019	Jul. 31, 2018
Document And Entity Information
Entity Registrant Name	Union Acquisition Corp.
Entity Central Index Key	1,725,206
Document Type	10-K
Document Period End Date	Jan. 31, 2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Fiscay year Focus	2,019
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Shell Company	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 111,464,000
Entity Common Stock, Shares Outstanding		14,375,000

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Current Assets
Cash and cash equivalents	$ 337,004	$ 112,067
Prepaid expenses	120,288
Total Current Assets	457,292	112,067
Deferred offering costs		121,467
Marketable securities held in Trust Account	117,864,549
Total Assets	118,321,841	233,534
Current Liabilities
Accounts payable and accrued expenses	92,252
Accrued offering costs		21,299
Promissory note - related party		200,000
Total Current Liabilities	92,252	221,299
Commitments
Ordinary Shares subject to possible redemption, 11,047,768 and -0- shares at redemption value as of January 31, 2019 and 2018, respectively	113,229,582
Shareholders' Equity
Preference Shares, $0.0001 par value; 1,000,000 authorized; none issued and outstanding
Ordinary Shares, $0.0001 par value; 100,000,000 shares authorized; 3,327,232 and 2,875,000 shares issued and outstanding (excluding 11,047,768 and -0- shares subject to possible redemption) as of January 31, 2019 and 2018, respectively	333	288
Additional paid-in capital	4,270,088	24,712
Retained earnings/(Accumulated deficit)	729,586	(12,765)
Total Shareholders' Equity	5,000,007	12,235
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 118,321,841	$ 233,534

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Jan. 31, 2019	Jan. 31, 2018
Statement of Financial Position [Abstract]
Ordinary Shares, subject to possible redemption	11,047,768	0
Preference Shares, Par value	$ 0.0001	$ 0.0001
Preference Shares, Authorized	1,000,000	1,000,000
Preference Shares, Issued	0	0
Preference Shares, Outstanding	0	0
Ordinary Shares, Par value	$ 0.0001	$ 0.0001
Ordinary Shares, Authorized	100,000,000	100,000,000
Ordinary Shares, Issued	3,327,232	2,875,000
Ordinary Shares, Outstanding	3,327,232	2,875,000

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)		3 Months Ended	12 Months Ended
		Jan. 31, 2018	Jan. 31, 2019
Income Statement [Abstract]
Operating costs		$ 12,765	$ 972,198
Loss from operations		(12,765)	(972,198)
Other income:
Dividend income on marketable securities held in Trust Account			1,714,549
Net income (loss)		$ (12,765)	$ 742,351
Weighted average shares outstanding, basic and diluted	[1]	2,500,000	3,204,688
Basic and diluted net loss per ordinary share		$ (0.01)	$ (0.28)
[1]	Excludes an aggregate of 11,047,768 shares subject to possible redemption at January 31, 2019 and an aggregate of 375,000 shares that were subject to forfeiture to the extent that the underwriters over-allotment option was not exercised in full at January 31, 2018.

STATEMENTS OF OPERATIONS (Paren

STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Ordinary Shares, subject to possible redemption	0	11,047,768
Forfeiture shares		375,000	375,000
Dividend income attributable to shares subject to possible redemption		$ 1,647,167

STATEMENTS OF CHANGES IN SHAREH

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Ordinary Shares [Member]	Additional Paid-In Capital [Member]	(Accumulated Deficit)/Retained Earnings [Member]	Total
Balance at Nov. 13, 2017
Ordinary shares issued to Initial Shareholders	$ 288	24,712		25,000
Ordinary shares issued to Initial Shareholders, shares	2,875,000
Net income (Loss)			(12,765)	(12,765)
Balance at Jan. 31, 2018	$ 288	24,712	(12,765)	$ 12,235
Balance, shares at Jan. 31, 2018	2,875,000			2,875,000
Sale of 11,500,000 Units, net of underwriting discounts and offering expenses	$ 1,150	112,273,853		$ 112,275,003
Sale of 11,500,000 Units, net of underwriting discounts and offering expenses, shares	11,500,000
Sale of 5,200,000 Private Placement Warrants		5,200,000		5,200,000
Ordinary shares subject to possible redemption	$ (1,105)	(113,228,477)		(113,229,582)
Ordinary shares subject to possible redemption, shares	(11,047,768)
Net income (Loss)			742,351	742,351
Balance at Jan. 31, 2019	$ 333	$ 4,270,088	$ 729,586	$ 5,000,007
Balance, shares at Jan. 31, 2019	3,327,232			3,327,232

STATEMENTS OF CHANGES IN SHAR_2

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)	12 Months Ended
	Jan. 31, 2019shares
Statement of Stockholders' Equity [Abstract]
Sale of units	11,500,000
Sale of private placement warrants	5,200,000

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2019
Cash Flows from Operating Activities:
Net income (loss)	$ (12,765)	$ 742,351
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Dividend income on marketable securities held in Trust Account		(1,714,549)
Changes in operating assets and liabilities:
Prepaid expenses		(120,288)
Accounts payable and accrued expenses		92,252
Net cash used in operating activities	(12,765)	(1,000,234)
Cash Flows from Investing Activities:
Investment of cash in Trust Account		(116,150,000)
Net cash used in investing activities		(116,150,000)
Cash Flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discounts paid		112,700,000
Proceeds from sale of Private Placement Warrants		5,200,000
Proceeds from issuance of ordinary shares to Initial Shareholders	25,000
Proceeds from promissory note from related party	200,000
Repayment of promissory note - related party		(200,000)
Payment of offering costs	(100,168)	(324,829)
Net cash provided by financing activities	124,832	117,375,171
Net Change in Cash and Cash Equivalents	112,067	224,937
Cash and Cash Equivalents - Beginning		112,067
Cash and Cash Equivalents - Ending	112,067	337,004
Non-cash Investing and Financing Activities:
Initial classification of ordinary shares subject to possible redemption		112,487,235
Change in value of ordinary shares subject to possible redemption		742,347
Offering costs included in accrued offering costs	$ 21,299

ORGANIZATION AND PLAN OF BUSINE

ORGANIZATION AND PLAN OF BUSINESS OPERATIONS	12 Months Ended
	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS	NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS Union Acquisition Corp. (the "Company") is a Cayman Islands exempted company incorporated on November 14, 2017. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a "Business Combination"). The Company’s efforts to identify a prospective target business is not limited to a particular industry or geographic region, although the Company is focusing its search for a target business on those located in Latin America. Effective February 14, 2018, the Company selected January 31 as its fiscal year end. All activity through January 31, 2019 relates to the Company's formation, its initial public offering (the “Initial Public Offering”), which is described below, searching for a Business Combination candidate, and activities in connection with the proposed Business Combination with Bioceres, Inc., a Delaware corporation (“Bioceres, Inc.”), as described in Note 8. The registration statement for the Company’s Initial Public Offering was declared effective on February 27, 2018. On March 2, 2018 the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the ordinary shares included in the Units offered, the “Public Shares”), which included the full exercise by the underwriters of their over-allotment option in the amount of 1,500,000 Units, at $10.00 per Unit, generating total gross proceeds of $115,000,000, which is described in Note 4. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of an aggregate of 5,200,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per warrant in a private placement (the “Private Placement”) to certain of the Company’s shareholders prior to the Initial Public Offering (the "Initial Shareholders"), generating total gross proceeds of $5,200,000, which is described in Note 5. Following the closing of the Initial Public Offering on March 2, 2018, an amount of $116,150,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement Warrants in the Private Placement was placed in a trust account (the “Trust Account”), which may be invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account, as described below. Transaction costs amounted to $2,724,997, consisting of $2,300,000 of underwriting fees and $424,997 of offering costs. The Company's management has broad discretion with respect to the specific application of the net proceeds of the sale of Units in the Initial Public Offering and the sale of the Private Placement Warrants in the Private Placement, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. The Company’s initial Business Combination must be with one or more target businesses that together have a fair market value of at least 80% of the balance in the Trust Account (excluding taxes payable on income earned on the Trust Account) at the time of the signing of an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. The Company will provide the holders of the Public Shares (the "Public Shareholders") with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the aggregate amount then on deposit in the Trust Account ($10.10 per share, plus any pro rata income earned and not previously released to the Company to pay its income and other tax obligations). The Company will proceed with a Business Combination only if it has net tangible assets of at least $5,000,001 upon consummation of the Business Combination and, in the case of a shareholder vote, a majority of the outstanding ordinary shares voted are voted in favor of the Business Combination. Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a "group" (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares. In connection with any shareholder vote required to approve any Business Combination, the Initial Shareholders and officers and directors and their affiliates have agreed (i) to vote any ordinary shares owned by them in favor of a Business Combination, (ii) not to redeem any of their ordinary shares in connection therewith and (iii) not to sell any their ordinary shares to the Company in a tender offer. The Company has until December 2, 2019 to complete a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including income (which income shall be net of taxes payable, and less up to $100,000 of income to pay liquidation expenses) divided by the number of then outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its Board of Directors, dissolve and liquidate, subject in each case to the Company's obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The proceeds deposited in the Trust Account could, however, become subject to claims of creditors. Therefore, the actual per-share redemption amount could be less than $10.10. In the event of a liquidation, the Public Shareholders will be entitled to receive a full pro rata interest in the Trust Account ($10.10 per share, plus any pro rata income earned, net of taxes payable, on funds in the Trust Account not previously released to the Company, and minus up to $100,000 of income to pay dissolution expenses). There will be no redemption rights or liquidating distributions with respect to the Public Warrants (as defined in Note 4), the Founder Shares (as defined in Note 6) or the Private Placement Warrants. The Public Warrants and Private Placement Warrants will expire worthless if the Company fails to complete a Business Combination within the Combination Period. In order to protect the amounts held in the Trust Account, Union Group International Holdings Limited (“UGI”), one of the Company’s initial shareholders and an affiliate of the Company’s Chairman of the Board, has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account below $10.10 per share. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, UGI will not be responsible to the extent of any liability for such third party claims. The Company will seek to reduce the possibility that UGI will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

LIQUIDITY AND GOING CONCERN

LIQUIDITY AND GOING CONCERN	12 Months Ended
	Jan. 31, 2019
Liquidity and Going Concern [Abstract]
LIQUIDITY AND GOING CONCERN	NOTE 2. LIQUIDITY AND GOING CONCERN As of January 31, 2019, the Company had $337,004 in its operating bank accounts, $117,864,549 in securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem its common stock in connection therewith and a working capital of $365,040. Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. The Company will need to raise additional capital through loans or additional investments from its Initial Shareholders, or its affiliates, officers, directors, or third parties. The Initial Shareholders, the Company’s officers and directors or their affiliates may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Emerging growth company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates. Cash and cash equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At January 31, 2019 and 2018, the Company had $337,004 and $0 of cash equivalents, respectively. Marketable securities held in Trust Account At January 31, 2019, the assets held in the Trust Account were substantially held in a money market fund comprised of U.S. Treasury Bills. Ordinary shares subject to possible redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at January 31, 2019, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet. Income taxes The Company accounts for income taxes under ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of January 31, 2019 and 2018, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction, and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented. Net loss per ordinary share Net loss per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Ordinary shares subject to possible redemption at January 31, 2019, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per ordinary share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. At January 31, 2018, weighted average shares were reduced for the effect of an aggregate of 375,000 ordinary shares that were subject to forfeiture if the over-allotment option was not exercised by the underwriters. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and the Private Placement to purchase 16,700,000 ordinary shares and (2) rights sold in the Initial Public Offering that convert into 1,150,000 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of the rights into ordinary shares of common stock are contingent upon the occurrence of future events. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. Reconciliation of net loss per ordinary share The Company’s net income (loss) is adjusted for the portion of income that is attributable to ordinary shares subject to possible redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net loss per ordinary share is calculated as follows: For the Period from November 14, 2017 Year Ended (Inception) Through January 31, January 31, 2019 2018 Net income (loss) $ 742,351 $ (12,765 ) Less: Income attributable to ordinary shares subject to possible redemption (1,647,167 ) — Adjusted net loss (904,816 ) (12,765 ) Weighted average shares outstanding, basic and diluted 3,204,688 2,500,000 Basic and diluted net loss per ordinary share $ (0.28 ) $ (0.01 ) Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk may consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage of $250,000. At January 31, 2019 and 2018, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair value of financial instruments The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature. Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

INITIAL PUBLIC OFFERING

INITIAL PUBLIC OFFERING	12 Months Ended
	Jan. 31, 2019
Initial Public Offering [Abstract]
INITIAL PUBLIC OFFERING	NOTE 4. INITIAL PUBLIC OFFERING Pursuant to the Initial Public Offering, the Company sold 11,500,000 Units at a purchase price of $10.00 per Unit, which includes the full exercise by the underwriters of their over-allotment option in the amount of 1,500,000 Units at $10.00 per Unit. Each Unit consists of one ordinary share, one right (“Public Right”) and one redeemable warrant (“Public Warrant”). Each Public Right entitles the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of a Business Combination (see Note 9). Each Public Warrant entitles the holder to purchase one ordinary share at a price of $11.50 per share (see Note 9).

PRIVATE PLACEMENT

PRIVATE PLACEMENT	12 Months Ended
	Jan. 31, 2019
Private Placement [Abstract]
PRIVATE PLACEMENT	NOTE 5. PRIVATE PLACEMENT Simultaneously with the Initial Public Offering, certain of the Initial Shareholders purchased an aggregate of 5,200,000 Private Placement Warrants at $1.00 per Private Placement Warrant (or an aggregate purchase price of $5,200,000). Each Private Placement Warrant is exercisable to purchase one ordinary share at an exercise price of $11.50. The proceeds from the sale of the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants. The Private Placement Warrants are identical to the Public Warrants underlying the Units except that the Private Placement Warrants (i) are not redeemable by the Company and (ii) may be exercised for cash or on a cashless basis, so long as they are held by the initial purchasers or any of their permitted transferees. If the Private Placement Warrants are held by holders other than the initial purchasers or any of their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. In addition, the Private Placement Warrants may not be transferable, assignable or salable until the consummation of a Business Combination, subject to certain limited exceptions.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jan. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares In December 2017, the Company issued an aggregate of 2,875,000 ordinary shares to the Initial Shareholders (the “Founder Shares”) for an aggregate purchase price of $25,000. The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture by the Initial Shareholders to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the Initial Shareholders would own 20% of the Company’s issued and outstanding shares after the Initial Public Offering (excluding any units purchased by them in the Initial Public Offering). As a result of the underwriters’ election to exercise their over-allotment option in full, 375,000 Founder Shares are no longer subject to forfeiture. The Initial Shareholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier of (i) one year after the date of the consummation of a Business Combination and (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing 150 days after a Business Combination, or earlier if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. Promissory Note – Related Party On December 4, 2017, the Company issued an unsecured promissory note to UGI, pursuant to which the Company borrowed an aggregate principal amount of $200,000 (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of (i) December 31, 2018, (ii) the consummation of the Initial Public Offering or (iii) the date on which the Company determined not to proceed with the Initial Public Offering. The Promissory Note was repaid upon the consummation of the Initial Public Offering on March 2, 2018. Administrative Services Agreement The Company entered into an agreement commencing on February 27, 2018 to pay two affiliates of certain of the Company’s officers and directors an aggregate monthly fee of $10,000 for office space, utilities and administrative support. The agreement will terminate upon the earlier of the consummation of a Business Combination or the Company’s liquidation. For the year ended January 31, 2019, the Company incurred $110,000 in fees for these services, of which $55,000 is included in accounts payable and accrued expenses in the accompanying balance sheet. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Initial Shareholders, the Company’s officers, directors or their affiliates may, but are not obligated to, loan the Company funds, from time to time or at any time, as may be required (the “Working Capital Loans”). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would either be paid upon consummation of a Business Combination, without interest, or, at the holder’s discretion, up to $1,500,000 of the Working Capital Loans may be converted into warrants at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such repayment.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7. COMMITMENTS AND CONTINGENCIES Registration Rights Pursuant to a registration rights agreement entered into on February 27, 2018, the holders of the Founder Shares, the Private Placement Warrants (and their underlying securities) and any warrants that may be issued upon conversion of the Working Capital Loans (and their underlying securities) are entitled to registration rights. The holders of a majority of these securities are entitled to make up to two demands that the Company register such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Warrants and warrants issued in payment of Working Capital Loans made to the Company (or underlying securities) can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements (see Note 9). Business Combination Marketing Agreement On February 27, 2018, the Company engaged certain advisors in connection with a Business Combination to assist the Company in holding meetings with its shareholders to discuss the potential Business Combination and the target business’ attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with a Business Combination, assist the Company in obtaining shareholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay these entities an aggregate cash fee for such services upon the consummation of a Business Combination of $4,065,250 (exclusive of any applicable finders’ fees which might become payable). If a Business Combination is not consummated for any reason, no fee shall be due or payable to the advisors.

BIOCERES BUSINESS COMBINATION

BIOCERES BUSINESS COMBINATION	12 Months Ended
	Jan. 31, 2019
Business Combinations [Abstract]
BIOCERES BUSINESS COMBINATION	NOTE 8. BIOCERES BUSINESS COMBINATION On November 8, 2018, the Company announced entry into a Share Exchange Agreement, by and among the Company, Joseph J. Schena, solely in his capacity as representative of the holders of the Company’s ordinary shares, and Bioceres, Inc. (the “ Exchange Agreement ”). Pursuant to the Exchange Agreement, among other things, (i) Bioceres S.A., an Argentine corporation and the parent company of Bioceres, Inc., will form a new entity, New Bioceres Inc., a Delaware corporation (“ Bioceres ”), and Bioceres, Inc. will contribute all of its assets and liabilities to Bioceres, in exchange for all of the outstanding stock of Bioceres (“ Bioceres stock ”); (ii) Bioceres, Inc. will convert into a Delaware limited liability company, Bioceres LLC; and (iii) Bioceres S.A. will contribute all of its equity interest in its majority owned subsidiary, Bioceres Semillas, S.A. (“ Bioceres Semillas ”) to Bioceres LLC (the transactions described in (i), (ii) and (iii), collectively, the “ Reorganization ”). Following the Reorganization, Bioceres LLC will contribute all if its equity interest in Bioceres and Bioceres Semillas to the Company in exchange for 27,116,174 ordinary shares of the Company (“ UAC Shares ”) and 7,500,000 warrants (“ UAC Warrants ”), each to purchase one UAC Share (the “ Exchange ,” and together with the Reorganization and the other transactions contemplated by the Exchange Agreement, the “ Business Combination ”). In addition, the consideration payable in connection with the minority ownership of Bioceres Semillas, if the minority holders exercise their tag along rights in connection with the consummation of the Business Combination, will be in the form of UAC Shares and/or cash and shall be equal to an amount not to exceed $2,000,000 to be payable to the minority holders of Bioceres Semillas by Bioceres S.A. The number of UAC Shares exchanged for Bioceres stock and all of the issued and outstanding stock of Bioceres Semillas owned by Bioceres LLC shall not exceed 27,116,174. Upon the consummation of the Business Combination, all of the Bioceres stock outstanding immediately prior to the effective time of the Exchange shall be automatically cancelled, extinguished and converted into 27,116,174 UAC Shares and 7,500,000 UAC Warrants. The consummation of the Business Combination is subject to customary closing conditions, including approval by the Company’s shareholders. In addition, consummation of the Business Combination is subject to (a) the Company having at least $5,000,001 of net tangible assets upon closing of the Business Combination, (b) the listing of the combined company’s shares on the New York Stock Exchange upon the closing of the Business Combination, (c) the consummation of the transactions contemplated by the Exchange Agreement, (d) the exercise of the Rizobacter option (as such term is defined in the Exchange Agreement); (e) the indebtedness of the Group Companies (as such term is defined in the Exchange Agreement) not to exceed $101 million; and (f) no Bioceres Material Adverse Effect (as such term is defined in the Exchange Agreement) having occurred.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Jan. 31, 2019
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	NOTE 9. SHAREHOLDERS’ EQUITY Preference Shares The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. At January 31, 2019 and 2018, there were no preference shares issued or outstanding. Ordinary Shares The Company is authorized to issue 100,000,000 ordinary shares, with a par value of $0.0001 per share. Holders of the ordinary shares are entitled to one vote for each ordinary share. At January 31, 2019 and 2018, there were 3,327,232 and 2,875,000 ordinary shares issued and outstanding (excluding 11,047,768 and -0- ordinary shares subject to possible redemption), respectively. Rights Each holder of a Public Right will receive one-tenth (1/10) of one ordinary share upon consummation of a Business Combination, even if a holder of such right converted all ordinary shares held by it in connection with a Business Combination. No fractional shares will be issued upon exchange of the Public Rights. No additional consideration will be required to be paid by a holder of Public Rights in order to receive its additional shares upon consummation of a Business Combination as the consideration related thereto has been included in the Unit purchase price paid for by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the Company will not be the surviving entity, the definitive agreement will provide for the holders of Public Rights to receive the same per share consideration the holders of the ordinary shares will receive in the transaction on an as-converted into ordinary shares basis and each holder of Public Rights will be required to affirmatively covert its rights in order to receive 1/10 of a share underlying each right (without paying additional consideration). The ordinary shares issuable upon exchange of the Public Rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company is unable to complete a Business Combination and the Company liquidates the funds held in the Trust Account, holders of Public Rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the Public Rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the Public Rights upon consummation of a Business Combination. Additionally, in no event will the Company be required to net cash settle the Public Rights. Accordingly, the Public Rights may expire worthless. Warrants The Public Warrants will become exercisable on the later of (a) the completion of a Business Combination or (b) 12 months from the closing of the Initial Public Offering. However, no Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the Public Warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the Public Warrants is not effective and current within 90 days following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. The Company may redeem the Public Warrants: ● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon not less than 30 days’ prior written notice of redemption; and ● if, and only if, the last sale price of the Company’s ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 10. FAIR VALUE MEASUREMENTS The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at January 31, 2019 and 2018, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: January 31, January 31, Description Level 2019 2018 Assets: Marketable securities held in Trust Account 1 $ 117,864,549 $ —

SELECTED QUARTERLY INFORMATION

SELECTED QUARTERLY INFORMATION (UNAUDITED)	12 Months Ended
	Jan. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
SELECTED QUARTERLY INFORMATION (UNAUDITED)	NOTE 11. SELECTED QUARTERLY INFORMATION (UNAUDITED) The following table presents summarized unaudited quarterly financial data for each of the four quarters for the year ended January 31, 2019 and for the period from November 14, 2017 (inception) through January 31, 2018. The data has been derived from the Company’s unaudited financial statements that, in management's opinion, include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of such information when read in conjunction with the financial statements and notes thereto. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period. First Second Third Fourth Quarter Quarter Quarter Quarter Year Ended January 31, 2019 Operating costs $ 208,471 $ 161,540 $ 224,138 $ 378,049 Dividend income $ 119,397 $ 457,091 $ 528,551 $ 609,510 Net income (loss) $ (89,074 ) $ 295,551 $ 304,413 $ 231,461 Basic and diluted loss per share $ (0.07 ) $ (0.04 ) $ (0.06 ) $ (0.11 ) Fourth Quarter For the Period from November 14, 2017 (Inception) Through January 31, 2018 Operating costs $ 12,765 Net loss $ (12,765 ) Basic and diluted loss per share $ (0.01 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jan. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).
Emerging growth company	Emerging growth company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At January 31, 2019 and 2018, the Company had $337,004 and $0 of cash equivalents, respectively.
Marketable securities held in Trust Account	Marketable securities held in Trust Account At January 31, 2019, the assets held in the Trust Account were substantially held in a money market fund comprised of U.S. Treasury Bills.
Ordinary shares subject to possible redemption	Ordinary shares subject to possible redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at January 31, 2019, ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheet.
Income taxes	Income taxes The Company accounts for income taxes under ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of January 31, 2019 and 2018, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction, and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented.
Net loss per ordinary share	Net loss per ordinary share Net loss per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. Ordinary shares subject to possible redemption at January 31, 2019, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per ordinary share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. At January 31, 2018, weighted average shares were reduced for the effect of an aggregate of 375,000 ordinary shares that were subject to forfeiture if the over-allotment option was not exercised by the underwriters. The Company has not considered the effect of (1) warrants sold in the Initial Public Offering and the Private Placement to purchase 16,700,000 ordinary shares and (2) rights sold in the Initial Public Offering that convert into 1,150,000 ordinary shares, in the calculation of diluted loss per share, since the exercise of the warrants and the conversion of the rights into ordinary shares of common stock are contingent upon the occurrence of future events. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. Reconciliation of net loss per ordinary share The Company’s net income (loss) is adjusted for the portion of income that is attributable to ordinary shares subject to possible redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net loss per ordinary share is calculated as follows: For the Period from November 14, 2017 Year Ended (Inception) Through January 31, January 31, 2019 2018 Net income (loss) $ 742,351 $ (12,765 ) Less: Income attributable to ordinary shares subject to possible redemption (1,647,167 ) — Adjusted net loss (904,816 ) (12,765 ) Weighted average shares outstanding, basic and diluted 3,204,688 2,500,000 Basic and diluted net loss per ordinary share $ (0.28 ) $ (0.01 )
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk may consist of cash accounts in a financial institution, which at times, may exceed the Federal depository insurance coverage of $250,000. At January 31, 2019 and 2018, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Fair value of financial instruments	Fair value of financial instruments The fair value of the Company's assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the financial statements, primarily due to their short-term nature.
Recently issued accounting standards	Recently issued accounting standards Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jan. 31, 2019
Accounting Policies [Abstract]
Schedule of Basic and Diluted Net Loss Per Ordinary Share	The Company’s net income (loss) is adjusted for the portion of income that is attributable to ordinary shares subject to possible redemption, as these shares only participate in the income of the Trust Account and not the losses of the Company. Accordingly, basic and diluted net loss per ordinary share is calculated as follows: For the Period from November 14, 2017 Year Ended (Inception) Through January 31, January 31, 2019 2018 Net income (loss) $ 742,351 $ (12,765 ) Less: Income attributable to ordinary shares subject to possible redemption (1,647,167 ) — Adjusted net loss (904,816 ) (12,765 ) Weighted average shares outstanding, basic and diluted 3,204,688 2,500,000 Basic and diluted net loss per ordinary share $ (0.28 ) $ (0.01 )

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at January 31, 2019 and 2018, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: January 31, January 31, Description Level 2019 2018 Assets: Marketable securities held in Trust Account 1 $ 117,864,549 $ —

SELECTED QUARTERLY INFORMATIO_2

SELECTED QUARTERLY INFORMATION (UNAUDITED) (Tables)	12 Months Ended
	Jan. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Summary of Unaudited Quarterly Financial Data	The following table presents summarized unaudited quarterly financial data for each of the four quarters for the year ended January 31, 2019 and for the period from November 14, 2017 (inception) through January 31, 2018. The data has been derived from the Company’s unaudited financial statements that, in management's opinion, include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of such information when read in conjunction with the financial statements and notes thereto. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period. First Second Third Fourth Quarter Quarter Quarter Quarter Year Ended January 31, 2019 Operating costs $ 208,471 $ 161,540 $ 224,138 $ 378,049 Dividend income $ 119,397 $ 457,091 $ 528,551 $ 609,510 Net income (loss) $ (89,074 ) $ 295,551 $ 304,413 $ 231,461 Basic and diluted loss per share $ (0.07 ) $ (0.04 ) $ (0.06 ) $ (0.11 ) Fourth Quarter For the Period from November 14, 2017 (Inception) Through January 31, 2018 Operating costs $ 12,765 Net loss $ (12,765 ) Basic and diluted loss per share $ (0.01 )

ORGANIZATION AND PLAN OF BUSI_2

ORGANIZATION AND PLAN OF BUSINESS OPERATIONS (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2019
Purchase price per unit sold in Initial Public Offering		$ 10.10
Proceeds from sale of Private Placement Warrants		$ 5,200,000
Investment of cash in Trust Account		116,150,000
Offering costs charged to stockholders' equity		2,724,997
Threshold for Company to recognize transaction as a business combination		5,000,001
Underwriting fees		2,300,000
Offering costs		424,997
Proceeds from business combination		5,000,001
Liquidation expenses		100,000
Dissolution expenses		$ 100,000
Private Placement Warrants [Member]
Number of purchased by initial shareholders		5,200,000
Purchase price per warrant		$ 1
Proceeds from sale of Private Placement Warrants		$ 5,200,000
IPO [Member]
Number of Units sold in Initial Public Offering		11,500,000
Purchase price per unit sold in Initial Public Offering		$ 10
Number of Units exercised by underwriters		1,500,000
Gross proceeds initial public offerings		$ 115,000,000

LIQUIDITY AND GOING CONCERN (Na

LIQUIDITY AND GOING CONCERN (Narrative) (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018	Nov. 13, 2017
Liquidity and Going Concern [Abstract]
Cash and cash equivalents	$ 337,004	$ 112,067
Marketable securities held in Trust Account	117,864,549
Working capital	$ 365,040

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Jan. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash equivalents	$ 337,004
FDIC insurance coverage	$ 250,000
Forfeiture shares	375,000	375,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contingent equity not included in computation of diluted loss per share	16,700,000
Rights Sold [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contingent equity not included in computation of diluted loss per share	1,150,000

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Basic and Diluted Net Loss Per Ordinary Share) (Details) - USD ($)		3 Months Ended					12 Months Ended
		Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2019
Accounting Policies [Abstract]
Net income (loss)		$ 231,461	$ 304,413	$ 295,551	$ (89,074)	$ (12,765)	$ 742,351
Less: Income attributable to ordinary shares subject to possible redemption							(1,647,167)
Adjusted net loss						$ (12,765)	$ (904,816)
Weighted average shares outstanding, basic and diluted	[1]					2,500,000	3,204,688
Basic and diluted net loss per ordinary share		$ (0.11)	$ (0.06)	$ (0.04)	$ (0.07)	$ (0.01)	$ (0.28)
[1]	Excludes an aggregate of 11,047,768 shares subject to possible redemption at January 31, 2019 and an aggregate of 375,000 shares that were subject to forfeiture to the extent that the underwriters over-allotment option was not exercised in full at January 31, 2018.

INITIAL PUBLIC OFFERING (Narrat

INITIAL PUBLIC OFFERING (Narrative) (Details)	12 Months Ended
	Jan. 31, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Purchase price per unit sold in Initial Public Offering	$ 10.10
IPO [Member]
Class of Warrant or Right [Line Items]
Number of Units sold in Initial Public Offering | shares	11,500,000
Purchase price per unit sold in Initial Public Offering	$ 10
Number of Units exercised by underwriters | shares	1,500,000
Public Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 11.50

PRIVATE PLACEMENT (Narrative) (

PRIVATE PLACEMENT (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2019
Class of Warrant or Right [Line Items]
Proceeds from sale of Private Placement Warrants		$ 5,200,000
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Number of purchased by initial shareholders		5,200,000
Purchase price per warrant		$ 1
Proceeds from sale of Private Placement Warrants		$ 5,200,000
Exercise price of warrants		$ 11.50

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)	Dec. 04, 2017	Dec. 31, 2017	Jan. 31, 2018	Jan. 31, 2019
Related Party Transaction [Line Items]
Stock issued during period, value			$ 25,000
Accounts payable and accrued expenses				$ 55,000
Threshold of Working Capital Loans that can be converted into warrants				$ 1,500,000
Conversion price per warrant				$ 1
Union Group International Holdings Limited [Member] | Unsecured Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument face amount	$ 200,000
Debt instrument maturity date description	The Promissory Note was non-interest bearing and payable on the earlier of (i) December 31, 2018, (ii) the consummation of the Initial Public Offering or (iii) the date on which the Company determined not to proceed with the Initial Public Offering.
Debt instrument repayment date			Mar. 2, 2018
Founder [Member]
Related Party Transaction [Line Items]
Stock issued during period, shares		2,875,000
Stock issued during period, value		$ 25,000
Number of shares subject to forfeiture		375,000
Number of shares no longer subject to forfeiture			375,000
Officers and Directors [Member]
Related Party Transaction [Line Items]
Aggregate monthly fee owed to related parties				$ 10,000
Expenses incurred during period with related party				$ 110,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Jan. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Aggregate cash fee owed to advisors for future business combinations	$ 4,065,250

BIOCERES BUSINESS COMBINATION (

BIOCERES BUSINESS COMBINATION (Details) - Bioceres [Member]	Nov. 08, 2018USD ($)shares
Business Acquisition [Line Items]
Number of ordinary shares exchanged in business combination	27,116,174
Amount payable to minority holders | $	$ 2,000,000
UAC Warrants [Member]
Business Acquisition [Line Items]
Number of warrants exchanged in business combination	7,500,000

SHAREHOLDERS' EQUITY (Narrative

SHAREHOLDERS' EQUITY (Narrative) (Details) - $ / shares	Jan. 31, 2019	Jan. 31, 2018
Stockholders' Equity Note [Abstract]
Preference Shares, Authorized	1,000,000	1,000,000
Preference Shares, Par value	$ 0.0001	$ 0.0001
Preference Shares, Issued	0	0
Preference Shares, Outstanding	0	0
Ordinary Shares, Authorized	100,000,000	100,000,000
Ordinary Shares, Par value	$ 0.0001	$ 0.0001
Ordinary Shares, Issued	3,327,232	2,875,000
Ordinary Shares, Outstanding	3,327,232	2,875,000
Ordinary Shares, subject to possible redemption	11,047,768	0
Redemption price of per warrant	$ 0.01	$ 0.01

FAIR VALUE MEASUREMENTS (Schedu

FAIR VALUE MEASUREMENTS (Schedule of Measured of Fair Value on Recurring Basis) (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	$ 117,864,549
Level 1 [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	$ 117,864,549

SELECTED QUARTERLY INFORMATIO_3

SELECTED QUARTERLY INFORMATION (UNAUDITED) (Summary of Unaudited Quarterly Financial Data) (Details) - USD ($)	3 Months Ended					12 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Operating costs	$ 378,049	$ 224,138	$ 161,540	$ 208,471	$ 12,765	$ 972,198
Dividend income	609,510	528,551	457,091	119,397		1,714,549
Net income (loss)	$ 231,461	$ 304,413	$ 295,551	$ (89,074)	$ (12,765)	$ 742,351
Basic and diluted loss per share	$ (0.11)	$ (0.06)	$ (0.04)	$ (0.07)	$ (0.01)	$ (0.28)